Clinical Trial Update: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing guselkumab to golimumab in psoriatic arthritis patients who are inadequate responders to TNF inhibitors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Golimumab (golimumab)
• Guselkumab (guselkumab)

Snippet

Sponsor: University of Pennsylvania | Conditions: Psoriatic Arthritis | Phase 3 | Status: RECRUITING